September Investor Webinar recording
Following completion of process development and scale‐up for the CAR‐iNKT manufacturing process and a positive pre‐IND meeting with the FDA for a first‐in‐human study of ALA‐101 in CD19‐positive blood cancers, the webinar discussed the next steps for Arovella and its opportunities in developing the iNKT cell platform. Presenting on the webinar will be CEO and MD, Dr Michael Baker.